Company / Debt per Share
Jazz Pharmaceuticals Debt per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
$88.37
FY2025
5-year range
$88.37 / $107.71
FY2021-FY2025
Trend
-9.9%
vs FY2024
Sector context
#3 of 82
Health Care
What the data says
Among 82 Health Care companies, Jazz Pharmaceuticals is in the bottom 4% for debt per share. Debt per Share has fluctuated over the past 10 years, ranging from $26.43 in FY2017 to $107.71 in FY2021.
Based on SEC 10-K filings.
88.37 in FY2025 with a 5-year CAGR of +18.8%. Ranks 3rd among 82 companies in Health Care.
Improved from $90.37 to $88.37 over the past 2 years.
Health Care sector context is included.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -1.6%
- 5-Year CAGR
- +18.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 82This company $88.37 Sector average $126.59
▼
-30.2% below sector average
Key checks
Key Insights
- In FY2025, debt per share decreased 9.9% year-over-year.
- Ranks #3 out of 82 companies in the Health Care sector.
- Peak debt per share was recorded in FY2021.
- Lowest debt per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $88.37 | -9.9% |
| FY2024 | $98.12 | +8.6% |
| FY2023 | $90.37 | -2.7% |
| FY2022 | $92.88 | -13.8% |
| FY2021 | $107.71 | +188.6% |
| FY2020 | $37.31 | +34.0% |
| FY2019 | $27.85 | +2.8% |
| FY2018 | $27.10 | +2.6% |
| FY2017 | $26.43 | -20.2% |
| FY2016 | $33.11 | +68.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026